hVIVO (LON:HVO) Stock Price Down 11.1% – Here’s Why

hVIVO plc (LON:HVO) was down 11.1% on Monday . The stock traded as low as GBX 6.04 and last traded at GBX 6.04. Approximately 2,010,683 shares changed hands during mid-day trading, a decline of 42% from the average daily volume of 3,452,664 shares. The stock had previously closed at GBX 6.80.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on HVO. Peel Hunt restated an “add” rating and set a GBX 10 price target on shares of hVIVO in a research note on Thursday, November 20th. Shore Capital decreased their price objective on hVIVO from GBX 35 to GBX 25 and set a “buy” rating on the stock in a report on Tuesday, September 23rd. Two analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of GBX 17.50.

hVIVO Stock Performance

The company has a debt-to-equity ratio of 33.86, a current ratio of 1.61 and a quick ratio of 1.16. The firm has a market cap of £41.53 million, a P/E ratio of 7.85 and a beta of 0.97. The stock’s 50 day moving average is GBX 6.20 and its two-hundred day moving average is GBX 8.43.

Insider Buying and Selling

In related news, insider Yamin Mo’ Khan bought 3,310,405 shares of the business’s stock in a transaction that occurred on Monday, December 15th. The stock was acquired at an average price of GBX 6 per share, for a total transaction of £198,624.30. Also, insider Stephen Pinkerton purchased 520,000 shares of the firm’s stock in a transaction that occurred on Monday, December 15th. The stock was bought at an average cost of GBX 6 per share, for a total transaction of £31,200. Corporate insiders own 4.43% of the company’s stock.

hVIVO Company Profile

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model. In addition, the company is developing a database of infectious disease progression data that include Disease in Motion platform, which comprises unique datasets, such as clinical, immunological, virological, and digital (wearable) biomarkers.